FDA Safety Changes for CME
The FDA safety label changes column offers clinicians the latest updates on adverse events, precautions, and warnings associated with many commonly used drugs. The column often includes additional information, such as the clinical evidence leading to the label change or administration of the drug in particular patient populations, to assist healthcare providers.
FDA Safety Changes
- FDA Safety Communication: Clobazam Linked With Serious Skin Reactions
- FDA Safety Alert: Reduce Operative Bleeding Risk in Patients Taking LMWHs
- FDA Safety Change: Antiseizure Drug Linked With Eye, Skin Abnormalities
- FDA Safety Change: Blood Clots Reported With Use of Leukemia Drug
- FDA Safety Change: Tigecycline Strongly Linked With Mortality Risk
- FDA Safety Change: Risk for Neuropathy With Fluoroquinolone Use
- FDA Safety Changes: Ketoconazole Linked With Liver Injury
- FDA Safety Changes: Use of Magnesium Sulfate to Stop Preterm Labor
- FDA Safety Changes: Valproate Use During Pregnancy
- FDA Safety Changes: Azithromycin Linked With Fatal Irregular Heart Rhythms
Medscape is the funder and CME provider of the programs listed on this page. The findings and conclusions in these activities do not necessarily represent the formal position of the Food and Drug Administration.